ADC Competition Heats Up In China But Caution, Pressure Also Mount
Multiple Partnerships Help Progress
After the anti-PD-1/L1 antibody and cell therapy rush, antibody-drug conjugates are quickly gaining attention in China as new technologies and deal-making activity heats up, but one first mover warns of potential over-crowding.
